These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 38710000)

  • 1. Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.
    Cacciaguerra L; Abdel-Mannan O; Champsas D; Mankad K; Krecke KN; Chen JJ; Syc-Mazurek SB; Redenbaugh V; Lopez-Chiriboga AS; Valencia-Sanchez C; Hemingway C; Tillema JM; Ciccarelli O; Pittock SJ; Hacohen Y; Flanagan EP
    Neurology; 2024 May; 102(10):e209303. PubMed ID: 38710000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
    Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
    JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS.
    Redenbaugh V; Chia NH; Cacciaguerra L; McCombe JA; Tillema JM; Chen JJ; Lopez Chiriboga AS; Sechi E; Hacohen Y; Pittock SJ; Flanagan EP
    Mult Scler; 2023 Jun; 29(7):799-808. PubMed ID: 37218499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.
    Sechi E; Krecke KN; Messina SA; Buciuc M; Pittock SJ; Chen JJ; Weinshenker BG; Lopez-Chiriboga AS; Lucchinetti CF; Zalewski NL; Tillema JM; Kunchok A; Monaco S; Morris PP; Fryer JP; Nguyen A; Greenwood T; Syc-Mazurek SB; Keegan BM; Flanagan EP
    Neurology; 2021 Sep; 97(11):e1097-e1109. PubMed ID: 34261784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
    Cacciaguerra L; Morris P; Tobin WO; Chen JJ; Banks SA; Elsbernd P; Redenbaugh V; Tillema JM; Montini F; Sechi E; Lopez-Chiriboga AS; Zalewski N; Guo Y; Rocca MA; Filippi M; Pittock SJ; Lucchinetti CF; Flanagan EP
    Neurology; 2023 Mar; 100(13):e1418-e1432. PubMed ID: 36690455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies.
    Zhao-Fleming HH; Valencia Sanchez C; Sechi E; Inbarasu J; Wijdicks EF; Pittock SJ; Chen JJ; Wingerchuk DM; Weinshenker BG; Lopez-Chiriboga S; Dubey D; Tillema JM; Toledano M; Yadav H; Flanagan EP
    Neurology; 2021 Sep; 97(13):e1351-e1358. PubMed ID: 34389648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS.
    Duan Y; Zhuo Z; Li H; Tian DC; Li Y; Yang L; Gao C; Zhang T; Zhang X; Shi FD; Barkhof F; Liu Y
    J Neurol Neurosurg Psychiatry; 2021 Jul; 92(7):709-716. PubMed ID: 33687975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease.
    Syc-Mazurek SB; Chen JJ; Morris P; Sechi E; Mandrekar J; Tillema JM; Lopez-Chiriboga AS; Lucchinetti CF; Zalewski N; Cacciaguerra L; Buciuc M; Krecke KN; Messina SA; Bhatti MT; Pittock SJ; Flanagan EP
    Neurology; 2022 Oct; 99(18):795-799. PubMed ID: 36175150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis.
    Molazadeh N; Akaishi T; Bose G; Nishiyama S; Chitnis T; Levy M
    Mult Scler Relat Disord; 2023 Dec; 80():105093. PubMed ID: 37949025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Joint radiomics and spatial distribution model for MRI-based discrimination of multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin-oligodendrocyte-glycoprotein-IgG-associated disorder.
    Luo X; Li H; Xia W; Quan C; ZhangBao J; Tan H; Wang N; Bao Y; Geng D; Li Y; Yang L
    Eur Radiol; 2024 Jul; 34(7):4364-4375. PubMed ID: 38127076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The burden of psychiatric morbidity in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD before and after neurological diagnosis.
    Tan YY; Saffari SE; Tye JSN; Peng X; Koh MJ; Mahmood ABSB; Tan JMM; Tan K; Yeo T
    Mult Scler Relat Disord; 2024 Sep; 89():105775. PubMed ID: 39053396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis.
    Cortese R; Battaglini M; Prados F; Gentile G; Luchetti L; Bianchi A; Haider L; Jacob A; Palace J; Messina S; Paul F; Marignier R; Durand-Dubief F; de Medeiros Rimkus C; Apostolos Pereira SL; Sato DK; Filippi M; Rocca MA; Cacciaguerra L; Rovira À; Sastre-Garriga J; Arrambide G; Liu Y; Duan Y; Gasperini C; Tortorella C; Ruggieri S; Amato MP; Ulivelli M; Groppa S; Grothe M; Llufriu S; Sepulveda M; Lukas C; Bellenberg B; Schneider R; Sowa P; Celius EG; Pröbstel AK; Granziera C; Yaldizli Ö; Müller J; Stankoff B; Bodini B; Barkhof F; Ciccarelli O; De Stefano N;
    Ann Neurol; 2024 Aug; 96(2):276-288. PubMed ID: 38780377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leptomeningeal Enhancement in Pediatric Anti-Myelin Oligodendrocyte Glycoprotein Antibody Disease, Multiple Sclerosis, and Neuromyelitis Optica Spectrum Disorder.
    Goldman-Yassen A; Lee A; Gombolay G
    Pediatr Neurol; 2024 Apr; 153():125-130. PubMed ID: 38382244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corpus callosum involvement in MOG antibody-associated disease in comparison to AQP4-IgG-seropositive neuromyelitis optica spectrum disorder and multiple sclerosis.
    Chia NH; Redenbaugh V; Chen JJ; Pittock SJ; Flanagan EP
    Mult Scler; 2023 May; 29(6):748-752. PubMed ID: 36691800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marked central canal T2-hyperintensity in MOGAD myelitis and comparison to NMOSD and MS.
    Webb LM; Cacciaguerra L; Krecke KN; Chen JJ; Sechi E; Redenbaugh V; Dubey D; Pittock SJ; Flanagan EP
    J Neurol Sci; 2023 Jul; 450():120687. PubMed ID: 37201267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS.
    Xu Q; Yang X; Qiu Z; Li D; Wang H; Ye H; Jiao L; Zhang J; Di L; Lei P; Dong H; Liu Z
    Mult Scler Relat Disord; 2023 Sep; 77():104797. PubMed ID: 37402345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
    Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
    Messina S; Mariano R; Roca-Fernandez A; Cavey A; Jurynczyk M; Leite MI; Calabrese M; Jenkinson M; Palace J
    Mult Scler; 2022 Feb; 28(2):217-227. PubMed ID: 34048323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.